Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP investors who were adversely affected by alleged securities fraud between September 27, 2023 and January 27, 2025. F ...

Core Viewpoint - Marex Group plc is under investigation for potential violations of federal securities laws following allegations of accounting misconduct, which may have led to significant financial misrepresentation [1][3]. Group 1: Allegations and Financial Impact - A report by NINGI Research claims that Marex has been involved in a multi-year accounting scheme, utilizing off-balance-sheet entities and misleading disclosures to hide losses and inflate profits [3]. - The report specifically mentions that Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, which it controls and trades with [3]. - Following the release of this report, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, resulting in financial harm to investors [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., and investors have until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, due to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices [1][3] Group 1: Allegations Against GeneDx - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [3] - The report alleges that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet required criteria [3] - It is noted that CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, suggesting insider knowledge of imminent risks [3] Group 2: Stock Price Impact - Following the allegations, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Legal Options for Investors - Bragar Eagel & Squire encourages investors who suffered losses in GeneDx to contact them to discuss their legal rights and options [1][4]

Core Viewpoint - Marex Group plc is under investigation for potential violations of federal securities laws following allegations of a multi-year accounting scheme that concealed significant losses and inflated profits [1][2]. Group 1: Allegations and Financial Impact - A report by NINGI Research claims that Marex has concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, which it controls and trades with [2]. - The report also alleges that Marex misclassified structured note issuance as income to inflate operating cash flow and generate non-cash trading profits [2]. - Following the news, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, resulting in financial injury to investors [3]. Group 2: Legal and Whistleblower Information - Glancy Prongay & Murray LLP is leading the investigation on behalf of Marex investors and is encouraging those with non-public information to consider aiding the investigation through the SEC Whistleblower Program, which offers rewards up to 30% of any successful recovery [5]. - The law firm has a strong track record in securities litigation, having been consistently ranked among the top firms in terms of settlements and recoveries for investors [6][7].

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for alleged violations of securities laws, specifically related to misleading statements about a Department of Justice investigation [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to Semler's actions between March 10, 2021, and April 15, 2025, during which investors are encouraged to contact the Schall Law Firm if they suffered losses [2]. - The complaint alleges that Semler made false and misleading statements regarding a DOJ investigation into potential violations of the False Claims Act, which were not disclosed to investors [4]. Group 2: Investor Participation - Investors who purchased Semler's securities during the class period are invited to join the lawsuit to recover their losses, with a deadline for participation set for October 29, 2025 [2]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].

Core Viewpoint - A class action securities lawsuit has been filed against PubMatic, Inc. alleging securities fraud that negatively impacted investors between February 27, 2025, and August 11, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that PubMatic's management made false statements and concealed critical information regarding a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [2]. - The lawsuit asserts that the positive statements made by the defendants about PubMatic's business and prospects were materially misleading and lacked a reasonable basis due to the aforementioned issues [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire were allegedly materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

SAN FRANCISCO, Sept. 2, 2025 /PRNewswire/ -- A securities fraud class action lawsuit styled Liggett Sr. v. C3.ai, Inc., et al., No. 3:25-cv-07129 (N.D. Cal.) has been filed and seeks to represent C3.ai (NYSE: AI) investors who purchased or otherwise acquired C3.ai securities between February 26, 2025 and August 8, 2025.The lawsuit comes after C3.ai reported preliminary financial results for its Q1 2026, which shockingly included expected revenues between only $70.2 million-$70.4 million, well below the midp ...